NEOGEN CORP

Neogen Corporation

What the company does

Neogen develops, manufactures, and markets a broad portfolio of food safety and animal safety products and services. The business is organized into two operating segments:

• Food Safety: Diagnostic tests and complementary products for food and animal feed producers and processors to detect contaminants, toxins, and allergens and to assess sanitation and quality. Offerings include diagnostic test kits, culture media, rapid readers, consumables, and data and risk-management software (Neogen Analytics).
• Animal Safety: Veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent and insect control products, genomics testing services, and related life-science products for animal health, biosecurity, and genetic improvement.

Neogen also provides genomics services and licenses certain technologies with royalty arrangements.

Key products and capabilities

• Food Safety

  • Test kits for natural toxins and allergens, microbial detection, ATP sanitation checks, culture media, Petrifilm plates, and molecular detection (e.g., MDS).
  • Instrumentation and readers; lateral-flow Reveal products; prepared media produced at multiple locations.
  • Megazyme (Ireland) supplies food quality and nutritional analysis reagents.
  • Neogen Analytics aggregates environmental monitoring, testing, and sanitation data.

• Animal Safety

  • Life‑science reagents for immunoassays and toxicology; drug-detection kits for veterinary and forensic testing; veterinary instruments and delivery systems (Ideal and Prima Tech).
  • Animal care products (digestive aids, nutritional supplements), companion animal products, antibiotics (Uniprim), vaccines (BotVax B), immunostimulants (EqStim), and other health products.
  • Rodent and insect control brands include Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard.
  • Genomics services for livestock and companion animals (to be divested to Zoetis under a 2026 agreement).

• Other offerings

  • Software and data services for environmental and food-safety data management.
  • Proprietary antibodies, immunoassay and nucleic acid testing technologies, plus licensed technologies with royalty components.

Major corporate actions and timing

• Genomics divestiture: On March 2, 2026, Neogen announced a definitive agreement to sell its Genomics business to Zoetis for $160.0 million. Closing is targeted by the end of the first half of fiscal 2027; regulatory reviews in Australia and New Zealand were underway as of July 2026.
• Petrifilm transition: Neogen is transitioning Petrifilm manufacturing from 3M to its Lansing site, with substantial completion anticipated in fiscal 2027. The transition spans multiple quarters and will include transition-related costs.
• Regulatory and approval activities continue for animal vaccines, certain pharmaceutical products, and international compliance matters.

Markets and customers

• Global footprint: Manufacturing and service locations in multiple countries; customers served worldwide through direct sales and an extensive distributor network.
• International exposure: International sales represented 51.2% of total revenues in fiscal 2026, 50.2% in 2025, and 49.7% in 2024.
• Distribution reach: The company sells through distributors in more than 100 countries and maintains direct-sales and field personnel for key markets.
• Geographic presence examples: United Kingdom/Europe/Middle East/Africa/India; Mexico and Latin America; Asia‑Pacific; Canada. The company maintains 28 international locations and sells through internal teams and distributors.

Employees and human capital

• Total employees: 2,636 worldwide as of May 31, 2026.
  • North America: 1,346
  • International: 1,290
• Sales and marketing: 817 domestic sales and marketing employees as of May 31, 2026.

Locations and production

• Principal locations:
  • Food Safety segment: 19 owned and 35 leased locations.
  • Animal Safety segment: 10 owned and 4 leased locations.
• International manufacturing and sites include the U.K., Ireland (Megazyme in Bray), Brazil, Wales (Clean‑Trace), and other facilities for Petrifilm, culture media, and molecular diagnostics.
• Production and supply:
  • Food safety diagnostics and culture media are produced in multiple U.S. and U.K. facilities, with some shipments from a Netherlands facility to Europe.
  • Animal health products are produced in FDA‑registered U.S. facilities; some components and packaging are manufactured in other U.S. and international sites.
  • Genomics labs are located in the U.S., Scotland, Brazil, Australia, China, and Canada.

Intellectual property

• Patents: Approximately 157 U.S. patents and 445 patents outside the U.S.; about 102 patent applications pending globally.
• Trademarks: Approximately 84 U.S. trademark registrations and 449 registrations outside the U.S.
• The company uses a mix of internally developed technology, licensed technology, and trade secrets, with royalty arrangements for certain licenses.

Corporate history and address

• Neogen Corporation was formed as a Michigan corporation in June 1981; operations began in 1982.
• Principal executive offices: 620 Lesher Place, Lansing, Michigan 48912-1595; telephone (517) 372-9200.
• Annual reports and SEC filings, including Form 10‑K and amendments, are available on the company website.

Revenue and financing highlights

• International sales comprised a majority of total revenues in recent years (51.2% in fiscal 2026).
• The company maintains a debt and liquidity structure that includes revolving credit facilities, term loans, and senior notes.
• Integration costs from the 3M Food Safety and Diagnostics (FSD) transaction and the Petrifilm transition are being managed alongside broader operational priorities.
• The Genomics divestiture and related regulatory reviews may affect future financial performance.

Risk and governance

• Risk factors discussed in public disclosures include integration and transaction risks from the 3M acquisition, international and currency exposure, tariffs and supply-chain considerations, cybersecurity, regulatory compliance, litigation, and risks tied to the Genomics divestiture.
• Governance structure includes board oversight, a Governance and Sustainability Committee, and formal risk‑management practices.

Summary Neogen operates two primarily mission-driven segments—Food Safety and Animal Safety—offering diagnostics, instruments, reagents, software, and related services worldwide. The company has a broad international presence, a large distributor network, and ongoing strategic actions including the Petrifilm manufacturing transition and the planned sale of its Genomics business to Zoetis.